Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

Trial Profile

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Ramipril (Primary) ; Valsartan (Primary)
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Acronyms AIM-3
  • Most Recent Events

    • 18 Feb 2016 According to ClinicalTrials.gov record, the primary endpoint has been amended.
    • 17 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 10 Jan 2012 Planned end date changed from 1 Feb 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top